DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE
To provide pharmaceutical compositions for treatment of neurological dysfunction, and uses thereof.SOLUTION: A pharmaceutical composition for reducing L-DOPA associated dyskinesias comprises a therapeutically effective amount of L-4-chlorokynurenine. A pharmaceutical composition for treating neuropa...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ALLEN E CATO H RALPH SNODGRASS JACK S HICKLIN |
| description | To provide pharmaceutical compositions for treatment of neurological dysfunction, and uses thereof.SOLUTION: A pharmaceutical composition for reducing L-DOPA associated dyskinesias comprises a therapeutically effective amount of L-4-chlorokynurenine. A pharmaceutical composition for treating neuropathic pain comprises a therapeutically effective amount of L-4-chlorokynurenine. The pharmaceutical composition for treating neuropathic pain consists essentially of L-4-chlorokynurenine in an amount of about 50 mg to about 1,800 mg per unit dose, together with pharmaceutically acceptable ingredients such as carriers and excipients.SELECTED DRAWING: None
【課題】神経機能障害の治療のための医薬組成物、及びその使用の提供。【解決手段】Ｌ−４−クロロキヌレニンの治療有効量を含む、Ｌ−ＤＯＰＡ関連ジスキネジアを軽減するための医薬組成物。治療有効量のＬ−４−クロロキヌレニンを含む、ニューロパチー性疼痛を治療するための医薬組成物。ニューロパチー性疼痛を治療するため、担体及び添加剤などの薬学的に許容される成分と共に、単位用量当たり約５０ｍｇから約１，８００ｍｇの量のＬ−４−クロロキヌレニンから本質的に成る、医薬組成物。【選択図】なし |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2020183400A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2020183400A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2020183400A3</originalsourceid><addsrcrecordid>eNrjZLB08Q92dHdVcPMP8g1WcPRzUQjxcA1yDHANDfF0VggNdg1W8HdT8NE10XX28PEP8veO9AsNcvXz9HPlYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBkYGhhbGJgYGjsZEKQIAy5MpBQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE</title><source>esp@cenet</source><creator>ALLEN E CATO ; H RALPH SNODGRASS ; JACK S HICKLIN</creator><creatorcontrib>ALLEN E CATO ; H RALPH SNODGRASS ; JACK S HICKLIN</creatorcontrib><description>To provide pharmaceutical compositions for treatment of neurological dysfunction, and uses thereof.SOLUTION: A pharmaceutical composition for reducing L-DOPA associated dyskinesias comprises a therapeutically effective amount of L-4-chlorokynurenine. A pharmaceutical composition for treating neuropathic pain comprises a therapeutically effective amount of L-4-chlorokynurenine. The pharmaceutical composition for treating neuropathic pain consists essentially of L-4-chlorokynurenine in an amount of about 50 mg to about 1,800 mg per unit dose, together with pharmaceutically acceptable ingredients such as carriers and excipients.SELECTED DRAWING: None
【課題】神経機能障害の治療のための医薬組成物、及びその使用の提供。【解決手段】Ｌ−４−クロロキヌレニンの治療有効量を含む、Ｌ−ＤＯＰＡ関連ジスキネジアを軽減するための医薬組成物。治療有効量のＬ−４−クロロキヌレニンを含む、ニューロパチー性疼痛を治療するための医薬組成物。ニューロパチー性疼痛を治療するため、担体及び添加剤などの薬学的に許容される成分と共に、単位用量当たり約５０ｍｇから約１，８００ｍｇの量のＬ−４−クロロキヌレニンから本質的に成る、医薬組成物。【選択図】なし</description><language>eng ; jpn</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201112&DB=EPODOC&CC=JP&NR=2020183400A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25544,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201112&DB=EPODOC&CC=JP&NR=2020183400A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ALLEN E CATO</creatorcontrib><creatorcontrib>H RALPH SNODGRASS</creatorcontrib><creatorcontrib>JACK S HICKLIN</creatorcontrib><title>DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE</title><description>To provide pharmaceutical compositions for treatment of neurological dysfunction, and uses thereof.SOLUTION: A pharmaceutical composition for reducing L-DOPA associated dyskinesias comprises a therapeutically effective amount of L-4-chlorokynurenine. A pharmaceutical composition for treating neuropathic pain comprises a therapeutically effective amount of L-4-chlorokynurenine. The pharmaceutical composition for treating neuropathic pain consists essentially of L-4-chlorokynurenine in an amount of about 50 mg to about 1,800 mg per unit dose, together with pharmaceutically acceptable ingredients such as carriers and excipients.SELECTED DRAWING: None
【課題】神経機能障害の治療のための医薬組成物、及びその使用の提供。【解決手段】Ｌ−４−クロロキヌレニンの治療有効量を含む、Ｌ−ＤＯＰＡ関連ジスキネジアを軽減するための医薬組成物。治療有効量のＬ−４−クロロキヌレニンを含む、ニューロパチー性疼痛を治療するための医薬組成物。ニューロパチー性疼痛を治療するため、担体及び添加剤などの薬学的に許容される成分と共に、単位用量当たり約５０ｍｇから約１，８００ｍｇの量のＬ−４−クロロキヌレニンから本質的に成る、医薬組成物。【選択図】なし</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLB08Q92dHdVcPMP8g1WcPRzUQjxcA1yDHANDfF0VggNdg1W8HdT8NE10XX28PEP8veO9AsNcvXz9HPlYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBkYGhhbGJgYGjsZEKQIAy5MpBQ</recordid><startdate>20201112</startdate><enddate>20201112</enddate><creator>ALLEN E CATO</creator><creator>H RALPH SNODGRASS</creator><creator>JACK S HICKLIN</creator><scope>EVB</scope></search><sort><creationdate>20201112</creationdate><title>DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE</title><author>ALLEN E CATO ; H RALPH SNODGRASS ; JACK S HICKLIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2020183400A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ALLEN E CATO</creatorcontrib><creatorcontrib>H RALPH SNODGRASS</creatorcontrib><creatorcontrib>JACK S HICKLIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ALLEN E CATO</au><au>H RALPH SNODGRASS</au><au>JACK S HICKLIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE</title><date>2020-11-12</date><risdate>2020</risdate><abstract>To provide pharmaceutical compositions for treatment of neurological dysfunction, and uses thereof.SOLUTION: A pharmaceutical composition for reducing L-DOPA associated dyskinesias comprises a therapeutically effective amount of L-4-chlorokynurenine. A pharmaceutical composition for treating neuropathic pain comprises a therapeutically effective amount of L-4-chlorokynurenine. The pharmaceutical composition for treating neuropathic pain consists essentially of L-4-chlorokynurenine in an amount of about 50 mg to about 1,800 mg per unit dose, together with pharmaceutically acceptable ingredients such as carriers and excipients.SELECTED DRAWING: None
【課題】神経機能障害の治療のための医薬組成物、及びその使用の提供。【解決手段】Ｌ−４−クロロキヌレニンの治療有効量を含む、Ｌ−ＤＯＰＡ関連ジスキネジアを軽減するための医薬組成物。治療有効量のＬ−４−クロロキヌレニンを含む、ニューロパチー性疼痛を治療するための医薬組成物。ニューロパチー性疼痛を治療するため、担体及び添加剤などの薬学的に許容される成分と共に、単位用量当たり約５０ｍｇから約１，８００ｍｇの量のＬ−４−クロロキヌレニンから本質的に成る、医薬組成物。【選択図】なし</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2020183400A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T16%3A29%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ALLEN%20E%20CATO&rft.date=2020-11-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2020183400A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |